SUPREME
COURT OF CANADA
Citation:
Sanofi-Aventis v. Apotex Inc., 2015 SCC 20, [2015] 2 S.C.R. 136
|
Date: 20150420
Docket:
35886
|
Between:
Sanofi-Aventis,
Sanofi-Aventis Deutschland GmbH
and
Sanofi-Aventis Canada Inc.
Appellants
and
Apotex Inc.
Respondent
- and -
Sanofi-Aventis,
Sanofi-Aventis Deutschland GmbH
and
Sanofi-Aventis Canada Inc.
Appellants
and
Apotex Inc.
Respondent
- and -
Sanofi-Aventis,
Sanofi-Aventis Deutschland GmbH
and
Sanofi-Aventis Canada Inc.
Appellants
and
Apotex Inc.
Respondent
- and -
Sanofi-Aventis,
Sanofi-Aventis Deutschland GmbH
and
Sanofi-Aventis Canada Inc.
Appellants
and
Apotex
Inc.
Respondent
and
Canadian Generic
Pharmaceutical Association
and
Canada’s Research-Based Pharmaceutical Companies
Interveners
Coram: McLachlin C.J. and Abella, Rothstein, Cromwell, Moldaver,
Karakatsanis, Wagner, Gascon and Côté JJ.
Reasons for
Judgment:
(paras. 1 and 2)
|
McLachlin C.J. (Abella, Rothstein, Cromwell, Moldaver,
Karakatsanis, Wagner, Gascon and Côté JJ. concurring)
|
Sanofi-Aventis v. Apotex Inc., 2015 SCC 20,
[2015] 2 S.C.R. 136
Sanofi-Aventis, Sanofi-Aventis Deutschland GmbH
and Sanofi-Aventis Canada Inc. Appellants
v.
Apotex Inc. Respondent
- and -
Sanofi-Aventis, Sanofi-Aventis Deutschland GmbH
and Sanofi-Aventis Canada Inc. Appellants
v.
Apotex Inc. Respondent
- and -
Sanofi-Aventis, Sanofi-Aventis Deutschland GmbH
and Sanofi-Aventis Canada Inc. Appellants
v.
Apotex Inc. Respondent
- and -
Sanofi-Aventis, Sanofi-Aventis Deutschland GmbH
and Sanofi-Aventis Canada Inc. Appellants
v.
Apotex Inc. Respondent
and
Canadian Generic Pharmaceutical Association
and Canada’s Research-Based
Pharmaceutical Companies Interveners
Indexed as: Sanofi-Aventis v. Apotex Inc.
2015 SCC 20
File No.: 35886.
2015: April 20.
Present: McLachlin
C.J. and Abella, Rothstein, Cromwell, Moldaver, Karakatsanis, Wagner, Gascon
and Côté JJ.
on appeal from the federal
court of appeal
Intellectual
property — Patents — Medicines — Manufacturer applied to market generic version
of drug — Patentees of drug applied for prohibition orders that triggered
statutory stay under Patented Medicines (Notice of Compliance) Regulations and prevented
manufacturer from selling generic for 24 months — Action for damages brought
under s. 8 of Regulations for delayed market entry — Court of Appeal holding
that trial judge did not err in determining liability period of 24 months, in
determining that patentees’ authorized generic version would have entered
market within three months and achieved 30 percent share of hypothetical market
within liability period, or in determining that manufacturer entitled to
compensation for lost sales of its generic version associated with unapproved
indications — Patented Medicines (Notice of Compliance) Regulations,
SOR/93-133.
APPEAL
from a judgment of the Federal Court of Appeal (Sharlow, Pelletier and Mainville
JJ.A.), 2014 FCA 68, 456 N.R. 279, 125 C.P.R. (4th) 403, [2014] F.C.J. No. 295
(QL), 2014 CarswellNat 700 (WL Can.), setting aside in part the judgment of Snider
J., 2012 FC 553, 410 F.T.R. 78, [2012] F.C.J. No. 620 (QL), 2012 CarswellNat
1646 (WL Can.). Appeal dismissed.
Andrew J. Reddon, Steven G. Mason, David Tait and Sanjaya
Mendis, for
the appellants.
Harry B. Radomski, Andrew Brodkin, David Scrimger and Benjamin Hackett, for the respondent.
Jonathan Stainsby, David W. Aitken and Devin Doyle, for the intervener the
Canadian Generic Pharmaceutical Association.
Allyson
Whyte Nowak and Jason Markwell, for the
intervener the Canada’s Research-Based Pharmaceutical Companies.
The judgment of the Court was delivered orally
by
[1]
The
Chief Justice — We are all of the view to dismiss the appeal substantially for the
reasons of the majority of the Court of Appeal.
[2]
The appeal is dismissed
with costs.
Judgment accordingly.
Solicitors for the
appellants: McCarthy Tétrault, Toronto.
Solicitors for the
respondent: Goodmans, Toronto.
Solicitors
for the intervener the Canadian Generic Pharmaceutical Association: Aitken
Klee, Toronto and Ottawa.
Solicitors
for the intervener the Canada’s Research-Based Pharmaceutical Companies: Norton
Rose Fulbright Canada, Toronto.